Pegylated liposomal doxorubicin (Doxil®) for metastatic breast cancer: The Cancer Research Network, Inc., experience

Alejandra T. Perez, Gabriel H. Domenech, Cynthia Frankel, Charles L. Vogel

Research output: Contribution to journalArticle

82 Scopus citations

Abstract

Pegylated liposomal doxorubicin (Doxil®) was formulated to improve the safety profile of doxorubicin. The major toxicities, mucositis and palmar-plantar erythrodysesthesia, are dose and schedule dependent, respectively. Anecdotal experience suggests that a dosage of 40 mg/m2 every 4 weeks is well tolerated. To evaluate the safety and efficacy of this regimen in women with metastatic breast cancer, we performed a retrospective chart review at a private practice. Forty women received a median initial dose of 42.5 mg/m2 usually every 4 weeks and a median cumulative dose of 135 mg/m2 (range: 40-595 mg/m2). There were 10 partial responses and seven patients with stable disease for more than 6 months resulting in a clinical benefit rate of 43% in the intent-to-treat analysis. The median time to progression was 4 months in all patients, 6.5 months in patients who had partial responses, and 10 months in patients who had stable disease for more than 6 months. There was no grade 4 toxicity. The only grade 3 toxicities were leukopenia in seven (18%)patients, mucositis in one (3%), and palmar-plantar erythrodysesthesia in one (3%). More studies are warranted to confirm our findings, which suggest that pegylated liposomal doxorubicin at a dosage of 40-45 mg/m2 every 4 weeks is clinically active in, and well tolerated by, women with metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)22-29
Number of pages8
JournalCancer Investigation
Volume20
Issue numberSUPPL. 2
DOIs
StatePublished - 2002

Keywords

  • Anthracycline
  • Chemotherapy
  • Doxorubicin
  • Drug delivery
  • Liposome
  • Metastatic breast cancer
  • Pegylated liposomal doxorubicin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Pegylated liposomal doxorubicin (Doxil®) for metastatic breast cancer: The Cancer Research Network, Inc., experience'. Together they form a unique fingerprint.

  • Cite this